Iron Triangle Partners LP Has $60.15 Million Stake in CVS Health Corporation $CVS

Iron Triangle Partners LP lifted its holdings in CVS Health Corporation (NYSE:CVS) by 6.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 797,900 shares of the pharmacy operator’s stock after acquiring an additional 47,900 shares during the period. CVS Health makes up approximately 8.6% of Iron Triangle Partners LP’s investment portfolio, making the stock its largest position. Iron Triangle Partners LP owned about 0.06% of CVS Health worth $60,154,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of CVS. Harbor Capital Advisors Inc. increased its holdings in shares of CVS Health by 72.1% during the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 142 shares during the period. Corundum Trust Company INC bought a new stake in shares of CVS Health in the third quarter valued at approximately $29,000. Front Row Advisors LLC increased its stake in CVS Health by 436.5% during the 2nd quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock worth $31,000 after acquiring an additional 371 shares during the period. Twin Peaks Wealth Advisors LLC acquired a new position in CVS Health in the 2nd quarter valued at $36,000. Finally, SOA Wealth Advisors LLC. lifted its position in shares of CVS Health by 36.9% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after acquiring an additional 131 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

CVS stock opened at $76.14 on Monday. The company has a market capitalization of $96.87 billion, a P/E ratio of 55.17, a PEG ratio of 0.79 and a beta of 0.49. CVS Health Corporation has a 52-week low of $58.35 and a 52-week high of $85.15. The company has a fifty day moving average price of $78.17 and a 200-day moving average price of $77.83. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The company had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. CVS Health’s payout ratio is presently 192.75%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CVS shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CVS Health in a research note on Monday, December 29th. JPMorgan Chase & Co. raised their target price on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Argus cut their price target on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, January 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of CVS Health in a research report on Wednesday, December 10th. Finally, Robert W. Baird boosted their price objective on shares of CVS Health from $82.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.05.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.